- Home
- CARM vs ADVB Comparison
CARM vs ADVB Comparison
Compare CARM & ADVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CARM
- ADVB
- Stock Information
- Founded
- CARM 2016
- ADVB 2014
- Country
- CARM United States
- ADVB United States
- Employees
- CARM N/A
- ADVB N/A
- Industry
- CARM Biotechnology: Pharmaceutical Preparations
- ADVB Medical Specialities
- Sector
- CARM Health Care
- ADVB Health Care
- Exchange
- CARM Nasdaq
- ADVB Nasdaq
- Market Cap
- CARM 12.1M
- ADVB 12.2M
- IPO Year
- CARM N/A
- ADVB 2025
- Fundamental
- Price
- CARM $0.26
- ADVB $0.48
- Analyst Decision
- CARM Hold
- ADVB
- Analyst Count
- CARM 5
- ADVB 0
- Target Price
- CARM $0.90
- ADVB N/A
- AVG Volume (30 Days)
- CARM 1.1M
- ADVB 249.8K
- Earning Date
- CARM 11-06-2025
- ADVB 11-03-2025
- Dividend Yield
- CARM N/A
- ADVB N/A
- EPS Growth
- CARM N/A
- ADVB N/A
- EPS
- CARM N/A
- ADVB N/A
- Revenue
- CARM $10,767,000.00
- ADVB N/A
- Revenue This Year
- CARM N/A
- ADVB N/A
- Revenue Next Year
- CARM N/A
- ADVB N/A
- P/E Ratio
- CARM N/A
- ADVB N/A
- Revenue Growth
- CARM N/A
- ADVB N/A
- 52 Week Low
- CARM $0.14
- ADVB $0.34
- 52 Week High
- CARM $1.27
- ADVB $4.10
- Technical
- Relative Strength Index (RSI)
- CARM 44.09
- ADVB 50.76
- Support Level
- CARM $0.24
- ADVB $0.43
- Resistance Level
- CARM $0.27
- ADVB $0.65
- Average True Range (ATR)
- CARM 0.03
- ADVB 0.05
- MACD
- CARM -0.00
- ADVB 0.00
- Stochastic Oscillator
- CARM 26.11
- ADVB 27.99
About CARM Carisma Therapeutics Inc.
CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.
About ADVB Advanced Biomed Inc. Common Stock
Advanced Biomed Inc operates through its subsidiaries that are responsible for the main operation and the design and development of the company's primary technologies and products. It has been focusing on the integration of multiple interdisciplinary technologies and established its microfluidic technology platform. Utilizing the physical and molecular biological characteristics of tumor cells, the company has developed various advanced and original research through the joint application of semiconductor technology and biotechnology. devices, A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre Chip and AC-1000 CTC Enrichment Chip and A+CellScan Chip, are designed to provide rapid and affordable assay products and services to cancer patients.